Next, two mechanisms of action, as α-glucosidase and SGLT-1 inhibitors, were evaluated, considering the main objectives of reducing hyperglycemia in DM patients is the prevention of carbohydrate hydrolysis (α-glucosidase) and absorption (SGLT-1) after food intake [49], and considering that the products contact the stomach and small intestine with oral administration, occurring where the α-glucosidases and SGLT-1 cotransporters function for the hydrolysis and absorption of carbohydrates [12,13]. Here, SLC5A1 is linked to Hyperglycemia.